Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 1.78 USD 1.14%
Market Cap: 78.3m USD
Have any thoughts about
Quince Therapeutics Inc?
Write Note

Quince Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Quince Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Quince Therapeutics Inc
NASDAQ:QNCX
Pre-Tax Income
-$31.6m
CAGR 3-Years
26%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Quince Therapeutics Inc
Glance View

Market Cap
77m USD
Industry
Biotechnology

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.

QNCX Intrinsic Value
2.65 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Quince Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-31.6m USD

Based on the financial report for Dec 31, 2023, Quince Therapeutics Inc's Pre-Tax Income amounts to -31.6m USD.

What is Quince Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-20%

Over the last year, the Pre-Tax Income growth was 39%. The average annual Pre-Tax Income growth rates for Quince Therapeutics Inc have been 26% over the past three years , -20% over the past five years .

Back to Top